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SARCOCYSTIS NE URONA DIAGNOSTIC 
PRIMER AND ITS USE IN METHODS OF 
EQUINE PROTOZOAL 
MYELOENCEPHALITIS DIAGNOSIS 
TECHNICAL FIELD 
The present invention relates to an ampli?cation primer 
and probe Which can be used in an in vitro diagnostic test for 
the presence of S. neurona in equine blood or cerebrospinal 
?uid. 
Sarcocystis neurona is responsible for the equine condi 
tion of protoZoal myelitis. The ampli?cation primer is sev 
enteen nucleotides in length and complementary to a unique 
section of the small ribosomal subunit of Sarcocystis 
neurona, nucleotide positions 1470—1487. The primer has 
the sequence 5‘ CCATTCCGGACGCGGGT-3‘(SEQ ID 
N011). 
BACKGROUND 
Equine protoZoal myeloencephalitis (EPM) is a treatable, 
but often fatal, central nervous system (CNS) disease of 
equids. It has not been reported among horses originating 
outside the Western hemisphere. Several hundred cases 
occur in North America annually. Although EPM has been 
reported in ponies, donkeys and most breeds of horses, the 
greatest incidence has been among thoroughbreds, 
standardbreds, and quarter horses.1 (See references section 
beloW.) The disease occurs as a result of infection With 
Sarcocystis neurona. MeroZoites multiply in neurons, leu 
cocytes and vascular endothelial cells of the CNS resulting 
in perivascular mononuclear cell in?ltration and necrosis of 
the neuropile. Antemortem diagnosis of EPM is dif?cult.2 
Clinical signs vary dramatically, depending upon the loca 
tion and severity of CNS lesions. The disease may mimic 
various neurological disorders of the horse. Clinicopatho 
logic data are frequently of little diagnostic value. 
Some methods of diagnosing equine parasitic and other 
infections are knoWn. For example, US. Pat. No. 4,740,456 
to Kuhn et al. discloses immunological methods for diag 
nosing active human neurocysticercosis, including a serum 
test and a cerebrospinal ?uid test. The test involves detecting 
an antigen or antigens of larval origin, speci?cally of Taenia 
solium larva. 
US. Pat. No. 4,759,927 to Dutta discloses a vaccine 
against Potomac Horse Fever comprising deactivated E. 
Risticii as the active agent. The patent also discloses an assay 
for detecting the presence of E. Risticii antibodies. 
US. Pat. No. 5,141,925 to Alroy et al. discloses a method 
for the prophylactic and therapeutic treatment of animals 
having a parasite able to cause Coccidiosis. 
US. Pat. No. 5,210,018 to NuZZolo et al. discloses an 
immunoenZymatic method for the detection of anti 
Plasmoa'ium falclparum-sporozoite antibodies in human 
blood. 
“Evidence for Sarcocystis as the etiologic agent of equine 
protoZoal myeloencephalitis”, Simpson et al., J ProtoZool 
(UNITED STATES) August 1980, 27 (3) p288—92, discloses 
the diagnosis of Equine protoZoal myeloencephalitis (EPM) 
in 10 horses. By electron microscopy, schiZonts Were found 
in intact host cells of the spinal cords or, more frequently, 
free in the extracellular spaces. Developmental stages of 
schiZonts differed morphologically, and the late stage of 
schiZogony Was characteriZed by endopolygeny. These ?nd 
ings permitted tentative identi?cation of the protoZoan as a 
Sarcocystis sp. Free meroZoites Were present in the extra 
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cellular spaces or in cells of the spinal cord. Pericytes of 
capillaries Were most frequently parasitiZed by meroZoites, 
but the cytoplasm of neurons, macrophages, intravascular 
and tissue neutrophils, and axons of myelinated nerve ?bers 
also contained these organisms. The presence of parasites in 
the cytoplasm of tissue and circulating neutrophils suggest 
that this putative Sarcocystis sp. may have a hematogenous 
phase of infection. 
“Immunohistochemical study to demonstrate Sarcocystis 
neurona in equine protoZoal myeloencephalitis”, Hamir et 
al., J. Vet. Diagn. Invest. (UNITED STATES) July 1993, 5 
(3) p418—22; discloses a 5-year (1985—1989) retrospective 
immunohistochemical study Was conducted using an avidin 
biotin complex (ABC) immunoperoxidase method to dem 
onstrate Sarcocystis neurona in histologically suspect cases 
of equine protoZoal myeloencephalitis (EPM). Primary anti 
bodies against S. neurona and S. cruzi Were utiliZed for the 
ABC technique. The ?ndings Were compared With those 
from cases in Which the organisms Were detected by exami 
nation of hematoxylin and eosin (HE)-stained neuronal 
sections. HE-stained sections detected the presence of the 
organisms in 20% of the suspect cases; Whereas the ABC 
technique con?rmed the presence of S. neurona in 51% and 
67% of the cases by S. neurona and S. cruzi antibodies, 
respectively. A revieW of clinical case histories shoWed that 
21/47 (45%) of the EPM horses With parasites in the tissue 
sections had prior treatment With antiprotoZoal drugs and/or 
steroids. Using the test results of S. neurona and S. cruzi as 
a standard reference, HE test sensitivity based on examina 
tion of up to 30 neuronal sections per case Was only 25%, 
and test speci?city Was 91%. 
“Equine protoZoal myeloencephalitis: Antigen analysis of 
cultured Sarcocystis neurona meroZoites”, Granstrom et al., 
J. Vet. Diagn. Invest. (UNITED STATES) January 1993, 
5(1) p 88—90; discloses antigens of cultured Sarcocystis 
neurona meroZoites Were examined using immunoblot 
analysis. Blotted proteins Were probed With S. cruzi, S. 
muris, and S. neurona antisera produced in rabbits, S. fayeri 
(pre- and post-infection) and S. neurona (pre- and post 
inoculation) sera produced in horses, immune sera from 7 
histologically con?rmed cases of equine protoZoal myeloen 
cephalitis (EPM), and pre-suckle serum from a neWborn 
foal. Eight proteins, 70, 24, 23.5, 22.5, 13, 11, 10.5, and 10 
Kd, Were detected only by S. neurona antiserum and/or 
immune serum from EPM-affected horses. Equine sera Were 
titered by the indirect immuno?uorescent antibody (IFA) 
method using air-dried, cultured S. neurona meroZoites. 
Anti-Sarcocystis IFA titers Were found in horses With or 
Without EPM. Serum titers did not correspond to the number 
of speci?c bands recogniZed on immunoblots. 
“A ?ve year (1985—1989) retrospective study of equine 
neurological diseases With special reference to rabies”, 
Hamir et al., J. Comp. Pathol. (ENGLAND) May 1992, 106 
(4) p411—21; discloses a retrospective study of horses 
necropsied betWeen 1985 and 1989 at a diagnostic labora 
tory of a veterinary school in North America is documented. 
In this investigation over 20 per cent of the horses had 
clinical neurological signs. Equine protoZoal myeloencepha 
litis (caused by Sarcocystis neurona) and cervical stenotic 
myelopathy (Wobbler syndrome) Were the most common of 
these disorders. HoWever, only four cases of equine rabies 
Were diagnosed during the 5-year study. The gross micro 
scopical and immunohistochemical ?ndings from these 
rabies-positive horses are documented. Immunoperoxidase 
tests for detection of rabies antigen in another 35 horses With 
non-speci?c encephalitis/encephalopathydid not reveal any 
positive cases. Based on this investigation, it appears that 
6,110,665 
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immunoperoXidase is a valid method for diagnosis of rabies 
When fresh tissues are not available for the ?uorescent 
antibody test. 
“Characterization of Sarcocystis neurona from a thor 
oughbred With equine protoZoal myeloencephalitis”, BoW 
man et al., appears in Cornell Vet. 1992, April 82(2):115, 
Cornell Vet. (UNITED STATES) January 1992, 82 (1) 
p41—52 and discloses morphological information for syn 
type material of the etiologic agent of equine protoZoal 
myeloencephalitis, Sarcocystis HQZU‘OI’LLZ. A clinical descrip 
tion of the horse from Which the organism Was isolated and 
the methodology used to immunosuppress the horse in an 
attempt to increase parasite numbers are also given. The 
description includes microscopic details observed both With 
light and transmission electron microscopy. Mainly stages 
from tissue are illustrated, but information is also presented 
on the development of the organism after inoculation on to 
monolayers of bovine monocytes. It is believed that the large 
numbers of organisms observed in this horse Were due to its 
having not received prior treatment With trimethoprimsul 
phonamide and the large amounts of corticosteroids that 
Were administered in order to facilitate isolation of the 
pathogen. 
“Sarcocystis neurona n. sp. (Protozoa: ApicompleXa), the 
etiologic agent of equine protoZoal myeloencephalitis”, 
Dubey et al., J Parasitol (UNITED STATES) April 1991, 77 
(2) p212—8; discloses Sarcocystis neurona n. sp. is proposed 
for the apicompleXan taXon associated With myeloencepha 
litis in horses. Only asexual stages of this parasite presently 
are knoWn, and they are found Within neuronal cells and 
leukocytes of the brain and spinal cord. The parasite is 
located in the host cell cytoplasm, does not have a parasi 
tophorous vacuole, and divides by endopolygeny. SchiZonts 
are 5—35 microns ><5—20 microns and contain 4—40 mero 
Zoites arranged in a rosette around a prominent residual 
body. MeroZoites are approximately 4><1 micron, have a 
central nucleus, and lack rhoptries. SchiZonts and meroZoi 
tes react With Sarcocystis cruzi antiserum but not With 
Caryospora bigenetica. Toxoplasma gondii, Hammondia 
hammondi, or Neospora caninum antisera in an immuno 
histochemical test. 
“Equine protoZoal myeloencephalitis”, Madigan et al., 
Vet. Clin. North Am. Equine Pract. (UNITED STATES) 
August 1987, 3 (2) p397—403; discloses Equine protoZoal 
myeloencephalitis (EPM) is a disease that produces neuro 
logic signs of brain or spinal cord dysfunction. The causative 
organism is believed to be a Sarcocystis species of protoZoa. 
A de?nitive diagnosis can only be made on histopathology 
of affected spinal cord or brain. No preventive measures or 
documented treatment is available at this time for suspected 
cases of EPM. 
Currently the only method of antemortem diagnosis of 
equine sarcocystis (EPM) is by Western Blot, Which detects 
the presence of antibodies against S. HQZU‘OI’LLZ. Blood con 
tamination of the spinal ?uid, or loss of integrity of the 
blood-brain barrier may result in false positive tests. A DNA 
based test according to the present invention circumvents 
these problems. Recently, progress has been made in the 
development of serological methods for EPM diagnosis. The 
availability of cultured meroZoites has made it possible to 
detect S. neuronal-speci?c antibodies in serum and cere 
brospinal ?uid of affected horses.3 Immunoblot analysis of 
these samples distinguishes betWeen eXposure to S. neurona 
and S. fayeri a common, non-pathogenic, coccidia of the 
horse. Previous serologic tests relied on S. cruzi bradyZoite 
antigen Which only detected antibodies to shared or cross 
reactive Sarcocystis spp. epitopes. Preliminary immunoblot 
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screening of several groups of horses in central Kentucky 
indicated that many horses are eXposed While feW develop 
clinical signs .4 At present, there is no method to directly 
detect and differentiate S. neurona from non-pathogenic 
Sarcocystis in live animals. 
There is a need in the art for a diagnostic method of 
detecting Equine protoZoal myeloencephalitis (EPM). The 
primer/probe of the present invention provides the ?rst 
diagnostic primer for the diagnosis of Equine protoZoal 
myeloencephalitis (EPM) caused by the parasite Sarcocysi 
[is HQZU‘OI’LLZ. 
DISCLOSURE OF THE INVENTION 
The present invention provides an ampli?cation primer/ 
probe Which can be used in an in vitro diagnostic test for the 
presence of S. neurona in equine blood or cerebrospinal 
?uid. Sarcocystis neurona is responsible for the equine 
condition of protoZoal myelitis. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIGS. 1(A)—(E) shoWs the relatedness of a 450 nt 
sequence from SRSU of S. neurona When compared to S. 
muris, S. gigantea, T gondii, S. capicanis, S. arieticanis, S. 
cruzi, S. tenella, E. tenella and C. parvum by comparison of 
sequences from the small ribosomal subunit of each. 
FIG. 2 shoWs a phylogenic tree depicting the relatedness 
of the complete gene sequence (1806 nt) of SRSU of S. 
neurona When compared to S. muris, S. gigantea, T gondii, 
S. capicanis, S. arieticanis, S. cruzi, S. tenella, E. tenella and 
C. parvum by comparison of sequences from the small 
ribosomal subunit of each. 
FIG. 3 shoWs a gel shoWing ef?cacy of the probe accord 
ing to the present invention. 
DESCRIPTION OF THE INVENTION 
Sarcocystis neurona is the etiologic agent of Equine 
protoZoal myeloencephalitis (EPM) Which Was isolated and 
described in 1991. There are limited means available for 
antemortem detection of this protoZoan in horses, and the 
life cycle and mode of transmission and pathogenesis of this 
disease remain unknoWn. 
The gene sequence of the Sarcocystis neurona small 
ribosomal subunit (SRSU) Was determined using poly 
merase chain reaction techniques and Sanger sequencing 
methods. The SRSU gene Was found to be 1806 nucleotides 
(nt) in length and have a G/C content of 46%. The small 
ribosomal subunit gene is an ideal molecular marker because 
it contains both sequences Which are highly conserved 
among species and sequences Which are variable. Variable 
regions are used to determine genetic relatedness of proto 
Zoal organisms. For example, FIG. 1 shoWs the relatedness 
of a 450 nt sequence from SRSU of S. neurona When 
compared to S. muris, S. gigantea, T gondii, S. capicanis, S. 
arieticanis, S. cruzi, S. tenella, E. tenella and C. parvum by 
comparison of sequences from the small ribosomal subunit 
of each. FIG. 2 shoWs a phylogenic tree depicting the 
6,110,665 
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relatedness of the complete gene sequence (1806 nt) of 
SRSU of S. neurona When compared to S. muris, S. 
gigantea, T gondii, S. capicanis, S. arieticanis, S. cruzi, S. 
tenella, E. tenella and C. parvum by comparison of 
sequences from the small ribosomal subunit of each. 
The present inventors have isolated an rDNA sequence 
Which can be used as a species-speci?c diagnostic probe and 
primer for Sarcocystis HQZU‘OI’LLZ. The methodology for iso 
lating the rDNA probe is set forth beloW. 
EXAMPLE 1 
Parasite Isolation and DNA Preparation 
MeroZoites of S. neurona (?fth isolate, strain SN5) Were 
cultured in vitro from the spinal cord of an infected horse 
Which Was necropsied at the University of Kentucky Live 
stock Disease Diagnostic Center. The parasite Was main 
tained in tissue culture in bovine monocytes (provided by C. 
A. Speer, Montana State University) supplemented With 
10% neonatal bovine serum (BioWhittaker, Walkersville, 
Md.) in RPMI 1640 media (BioWhittaker, Walkersville, 
Md.). Culture media Were removed from the culture vials, 
centrifuged at 800><G for 20 min to pellet the cells, then 
resuspended in Hanks balanced salt solution (BioWhittaker, 
Walkersville, Md.). The suspension of parasites and bovine 
monocytes Was layered above 1 ml of Percoll (Sigma, St. 
Louis, M0.) at a speci?c gravity of 1.070, and centrifuged at 
400><G for 20 min. MeroZoites Were found in the pellet, 
While the bovine monocytes Were found at the Hanks 
balanced salt solution-percoll interface. 
Approximately 5><106 meroZoites Were Washed in 1 ml 
phosphate-buffered saline (PBS), then resuspended in 20 pl 
PBS, and 200 pl of 50% Chelex-100 (Bio-Rad, Richmond, 
Calif). S. neurona DNA Was released by boiling this sus 
pension for 5 min. The sample Was subsequently quenched 
on ice for 5 min, and centrifuged. This supernatant Was used 
in the polymerase chain reaction (PCR) for the ampli?cation 
of the small ribosomal subunit gene. 
DNA Ampli?cation 
The PCR (Saiki et al., 1988) Was performed using eukary 
otic speci?c universal ampli?cation primers developed by 
Medlin et al., (1988). The described ampli?cation protocol 
Was modi?ed to optimiZe DNA yield. The “hot start” tech 
nique (Mullis, 1991) Was employed to limit mispriming at 
the onset of the reaction. Ampli?cation primers, MgCl2, and 
dNTP in PCR buffer (10 mM Tris-HCl, pH=8.3, 50 mM 
KCl) Were placed in 0.5 ml microcentrifuge tubes, and 
overlaid With 40 pl paraf?n Wax. Ten pl of Chelex superna 
tant and Taq polymerase (1.25 U, Amplitaq, Perkin-Elmer, 
NorWalk, Conn.) in PCR buffer Were overlaid on the Wax, 
and the microcentrifuge tubes Were placed in a thermocycler 
(Perkin-Elmer, NorWalk, Conn.). The ?nal concentrations of 
reagents Were 0.5 pM of each primer, 2 mM MgCl2 and 500 
pM of each deoxynucleotide. 
Denaturation of the DNA in the reactions Was accom 
plished by heating to 94° C. for 1 min. The annealing 
temperature Was 55° C. for 1 min, and the elongation 
temperature Was 72° C. for 2 min. These sequential incu 
bations Were repeated for 5 cycles, and then 30 additional 
cycles Were performed at the same conditions, With the 
exception of an annealing temperature of 50° C. for 1 min. 
The ?nal primer extension Was continued for 7 min to permit 
complete elongation of all ampli?ed product. 
Cloning into a pT7Blue Vector 
The PCR product Was puri?ed by ultra?ltration 
(KroWcZynska and Henderson, 1992) using microcon-100 
microconcentrators (Amicon, Beverly, Mass.). The ampli 
?ed product Was directly ligated into a pT7Blue vector 
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(Novagen, Madison, Wis.) and transformed according to the 
recommendations of the manufacturer. Transformed cells 
Were selected by culturing on LB agar plates containing 50 
pig/ml ampicillin and 15 pig/ml tetracycline. Colonies con 
taining PCR product insert Were selected using blue/White 
screening, by the addition of 40 pl of 20 mg/ml X-gal in 
dimethyl formamide, and 4 pl 200 mg/ml IPTG per 100 mm 
plate. Plates Were incubated for 12 to 24 hours (Sambrook, 
Fritsch and Maniatis, 1989). White colonies Were screened 
for insert by PCR. Individual colonies Were scraped from the 
plate, and diluted in 20 pl of sterile Water in 1.5 ml 
microcentrifuge tubes. These Were boiled for 2 min to 
release plasmid DNA, and 10 pl of supernatant Was used in 
the PCR protocol described above. TWelve positive clones 
Were identi?ed in this manner, and tWo Were arbitrarily 
chosen for sequencing. 
Dideoxynucleotide Sequencing and Analysis 
Small scale plasmid puri?cations Were performed for tWo 
positive clones, by a protocol modi?ed from Sambrook et al. 
(1989). Alkaline denaturation of these plasmid solutions Was 
performed to yield single stranded template. Sanger 
sequencing reactions Were performed using these templates. 
Primers used for sequencing included primers complemen 
tary to regions of the vector ?anking the insert, and also 
synthetic primers complementary to conserved regions of 
the eukaryotic small ribosomal subunit gene (ElWood et al., 
1985). Additional internal primers (840E: 5‘ 
GGATTTCGGT TCTATTTTGT TGG 3‘(SEQ ID N012, and 
1055R: 5‘ GTTTCAGCCT TGCGACCAT 3‘(SEQ ID N013) 
Were designed from the partial sequence to determine the 
complete sequence. 
The complete gene sequence of the small ribosomal 
subunit of S. neurona has 1806 nt. Aspeci?c 450 nt sequence 
fragment from SRSU of S. neurona Was also obtained and is 
disclosed. 
EXAMPLE 2 
Various ampli?cation primers for the SRSU gene Which 
are species-speci?c for Sarcocystis neurona Were tested. The 
ampli?cation primer for Sarcocystis neurona SRSU With 
species speci?city is seventeen nucleotides in length and 
complementary to a unique section of the small ribosomal 
subunit of Sarcocystis HQZU‘OI’LLZ. The unique ampli?cation 
primer encompasses nucleotide positions 1470—1487. The 
primer has the sequence: 
5‘-CCATTCCGGACGCGGGT- 3‘(SEQ ID N011). The 
primer/probe may be modi?ed at the 3‘ end by adding 
1—5 nucleotides, such that the primer/probe maintains 
the function of the original probe and hybridiZes spe 
ci?cally to Sarcocystis neurona small ribosomal sub 
unit. 
1470R Ampli. Primer: 5‘ CCATTCCGGACGCGGGT 
3‘(SEQ ID N011) MW=5267 
The 1470 R primer can be coupled to a detectable label 
and used as a diagnostic probe for the detection of Sarcocytis 
HQZU‘OI’LLZ. The detectable label may be selected from the 
group consisting of chromophores, ?uorophores, chemilu 
minescent materials and radioisotopes. Alternatively the 
primer may be used as a PCR primer as set forth beloW. 
EXAMPLE 3 
The advent of DNA based diagnostic assays has facili 
tated rapid, accurate identi?cation of micro-organisms 
through the use of species-speci?c nucleotide sequences. 
Generally, DNA probes have been developed from unique 
gene or intergenic sequences for DNA probes, or from 
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repetitive elements. In addition, development of the poly 
merase chain reaction (PCR) has greatly increased the speed 
at Which neW diagnostic assays can be developed.5 The time 
required to construct DNA libraries or clone speci?c DNA 
fragments has been reduced considerably by the ability to 
directly amplify the desired DNA region. 
The methodology for the nested polymerase chain reac 
tion (PCR) procedure used to conduct the diagnostic assay 
according to the present invention is set forth beloW. 
Nested PCR Diagnostic Method 
I. Required Reagents/Supplies/Equipment 
A. Supplies: 
Sterile 1.5 ml. microfuge tubes 
Sterile 0.5 ml. microfuge tubes 
Blue (?rst stage) 
YelloW (second stage) 
PCR Wax beads (created by dropping 30 pl hot paraf?n 
Wax on tin foil) 
forceps for Wax beads 
1.5 and 0.5 ml tube racks 
styrofoam ice cooler 
ice 
dedicated 1000 pl, 200 pl pipetman pipettors sterile, 
plugged tips for 1000 pl and 20 pl 
Thermocycler (48 reactions) 
Dedicated microcentrifuge 
B. Reagents: 
Millipore Water, sterilized and in 1 ml. aliquots (store in 
freeZer) 
DMSO, in 1 ml. aliquots (store aWay from light in box) 
Perkin-Elmer 10><PCR buffer 
Perkin-Elmer dNTPs, 10 mM per each, mixed together to 
form a single dNTP mixture containing 2.5 mM each 
nucleotide 
Perkin-Elmer Mg2Cl, 25 mM Primer 1470R (unique 
primer, reverse primer, ?rst stage), 10 mM, 5‘ 
CCATTCCGGACGCGGGT- 3‘(SEQ ID NO:1) Primer 
1184F (forWard primer, ?rst stage), 10 mM 
5‘ CCAGGCGTGGAGCTGCG-3‘(SEQ ID NO:4) Primer 
1055F (forWard primer, second stage), 10 mM 
5‘ GGTGGTGGTGCATGGCCG-3‘(SEQ ID NO:5) 
Primer 1475R (reverse primer, second stage), 10 mM 
5‘ GCGCGTGGCCCAGAAC-3‘(SEQ ID NO:6) (Primers 
may be synthesiZed on Applied Biosystems DNA 
synthesiZer) 
Ethidium Bromide 
DNA 100 bp ladder 
II. First Stage Reaction: 
A. The nested PCR reaction With hot start technique is set 
up in several stages. First, the hot start technique requires a 
loWer reaction including the primers and dNTPs in PCR 
buffer. The Wax is overlaid and melted over the loWer 
reaction mixture. The upper reaction containing the DNA 
template (in this case, cerebrospinal ?uid (CSF)) and Taq 
polymerase are placed in PCR buffer on top of the Wax. A 
drop (20 to 40 82 l) of sterile mineral oil is put on top to 
prevent excessive evaporation from the upper reaction mix 
ture. The entire tube is then spun brie?y to collect the ?uid 
at the bottom of the tube. 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
B. LoWer Reaction Mixture 
‘X 1’ ‘X 50’ 
Reagents (#1) Concentrations (,ul) 
P1184F 5.00 1 mM 250.00 
P1470R 5.00 1 mM 250.00 
MgCl2 8.00 4 mM 400.00 
dNTPs 4.00 1 mM 200.00 
10 X PCRB 2.50 1 X 125.00 
(+MgCl2) 
DMSO 2.50 5% 125.00 
mpH2O 3.00 — 150.00 
Reaction Volume 30.00 — 1500.00 
f = forWard primer; 
r = reverse primer 
The loWer reaction mixture is made up on 50 reaction 
quantities in a 1.5 ml microcentrifuge tube. This mixture 
(labelled “#1”, and dated) may be froZen for at least 1 month 
safely. When the nested reaction is to be performed, the tube 
is sloWly thaWed, mixed by pipetting up and doWn, then 30.0 
pl aliquots are placed into 48 blue 0.5 ml microfuge tubes. 
A Wax bead (PCR gem) is placed in the tube over the 
solution. The tubes are placed in the therinocycler at 80° C. 
for 5 minutes to melt the Wax, and then cooled to 4° C. to 
harden the Wax. Alternatively, the tubes may be placed in a 
Water bath (>65° C.) for about 5—10 minutes, then removed 
carefully and placed in a refrigerator for a feW minutes. 
C. Upper Reaction Mixture 
‘X 1’ “X 50’ 
Reagents (#1) Concentrations (,ul) 
mpH2O 7.25 — 362.50 
10 X PCRB 2.50 1 X 125.00 
Taq 0.25 _ 12.50 
Template 10.00 — — 
Reaction Volume 20.00 — 500.00 
The upper reaction mixture must be made up fresh, and 
chilled in ice throughout the procedure. The reagents must 
be added to the upper reaction mixture in order, so that the 
PCR buffer is in the solution before the Taq is added. The 
upper reaction mixture, not including the DNA template 
(CSF) is made up and then 10 pl aliquots are placed over the 
Wax into the blue microcentrifuge tubes containing the loWer 
reaction. 
Forty clinical samples can be tested per run, With seven 
Water controls and a positive S. neurona control. Preferably, 
about ten pl of each clinical cerebrospinal ?uid (CSF) is 
placed into a tube, and mixed With the upper reaction 
mixture by pipetting up and doWn. Care must be taken to 
avoid cross-contamination. The tubes are numbered 1 to 48, 
With numbers 1, 8, 15, 22, 29, 38, and 47 as Water, or reagent 
controls. These should be done in order for internal control. 
Number 48 is the positive S. neurona control. The reagent 
controls Will have the same Water tube Which Was used for 
the reaction setup as the “DNA template” to control for the 
accidental carryover of PCR product into this Water. Each 
reaction tube should then be overlaid With a drop of sterile 
mineral oil to avoid evaporation. 
D. Thermal-cycle Pro?le 
The tubes are placed in the thermal-cycler, and the ampli 
?cation protocol folloWs: 
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Cycle Temperature Duration 
1 Denaturing temp: 92 C. 2 min 
Annealing temp: 58 C. 30 min 
Extension temp: 74 C. 1 min 
2—6 Denaturing temp: 92 C. 30 sec 
Annealing temp: 58 C. 30 sec 
Extension temp: 74 C. 1 min 
7—31 Denaturing temp: 92 C. 30 sec 
Annealing temp: 54 C. 30 sec 
Extension temp: 74 C. 1 min 
32 Denaturing temp: 92 C. 30 sec 
Annealing temp: 54 C. 30 sec 
Extension temp: 74 C. 7 min 
33 Soak temp: 4 C. Until removed 
Samples are removed, and the Wax is pierced With a sterile 
pipette tip. Then, 10 pl of the product is used as the DNA 
template for the second stage reaction. 
III. Second Stage Reaction 
A. It is critical that no PCR carryover occur, and therefore, 
the entire procedure is done in a UV-clean area. Addition of 
the PCR product from the ?rst reaction, is performed in a 
different area, so as not to risk contamination of “clean” 
area. 
B. LoWer Reaction Mixture 
‘X 1’ ‘X 50” 
Reagents (#1) Concentrations (,ul) 
P1055F 5.00 1 mM 250.00 
P1475R 5.00 1 mM 250.00 
MgCl2 4.00 1 mM 200.00 
dNTPs 4.50 1 mM 200.00 
10 X PCRB 2.50 1 X 125.00 
mpH2O 8.50 — 425.00 
Reaction Volume 30.00 — 1500.00 
The loWer reaction mixture is made up in 50 reaction 
quantities in a 1.5 ml microcentrifuge tube. This mixture 
(labelled “#2”, and dated) may be frozen for at least 1 month 
safely. 
When the nested reaction is to be performed, the tube is 
sloWly thawed, mixed by pipetting up and doWn, then 30.0 
pl aliquots are placed into 48 yelloW 0.5 ml microfuge tubes. 
A Wax bead (PCR gen) is placed in the tube over the 
solution. The tubes are placed in the thermocycler at 80° C. 
for 5 minutes to melt the Wax, and then cooled to 4° C. to 
harden the Wax. Alternatively, the tubes may be placed in a 
Water bath (>65° C.) for about 5—10 minutes, then removed 
carefully and placed in a refrigerator for a feW minutes. 
C. Upper Reaction Mixture 
‘X 1’ ‘X 50’ 
Reagents (#1) Concentrations (,ul) 
mpH2O 7.25 — 362.50 
10 X PCRB 2.50 1 X 125.00 
Taq 0.25 _ 12.50 
Template 10.00 — — 
Reaction Volume 20.00 500.00 
The upper reaction mixture must be made up fresh, and 
chilled in ice throughout the procedure. The reagents are 
added to the upper reaction mixture in order, so that the PCR 
buffer is in the solution before the Taq is added. The upper 
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reaction mixture, not including the DNA template (CSF) is 
made up and then 10 pl aliquots are placed over the Wax into 
the yelloW microcentrifuge tubes containing the loWer reac 
tion. 
Ten pl of each blue tube (?rst stage) reaction is placed into 
a tube, and mixed With the upper reaction mixture by 
pipetting up and doWn. Care must be taken to avoid cross 
contamination. The tubes are numbered 1 to 48, to corre 
spond to the same tubes from Which product Will be used for 
template. Each reaction tube is then overlaid With a drop of 
sterile mineral oil to avoid evaporation. 
D. Thermal-cycle Pro?le 
The tubes are placed in the thermal-cycler, and the ampli 
?cation protocol folloWs: 
Cycle Temperature Duration 
1 Denaturing temp: 92 C. 2 min 
Annealing temp: 57 C. 30 min 
Extension temp: 74 C. 1 min 
2—6 Denaturing temp: 92 C. 30 sec 
Annealing temp: 57 C. 30 sec 
Extension temp: 74 C. 1 min 
7—31 Denaturing temp: 92 C. 30 sec 
Annealing temp: 53 C. 30 sec 
Extension temp: 74 C. 1 min 
32 Denaturing temp: 92 C. 30 sec 
Annealing temp: 53 C. 30 sec 
Extension temp: 74 C. 7 min 
33 Soak temp: 4 C. Until removed 
Samples are removed, and the Wax is pierced With a sterile 
pipette tip. Then, the PCR product is run out on a horizontal 
gel apparatus in a TAE 1% agarose gel at 100 V for about 
2—3 hours. The band should be about 250 bp in length When 
compared to the DNA 100 bp latter. Presence of a band is 
determined by EtBr staining. Stained band indicates Sarco 
cystis neurona is present in specimen. 
In an alternative embodiment, the conditions for PCR 
using the species speci?c primer of the present invention 
folloW: PCR Conditions LoWer reaction mix 
X1 X5 X1 X5 X1 X5 
1055F 2.5 12.5 2.5 12.5 2.5 12.5 
1470R 2.5 12.5 2.5 12.5 2.5 12.5 
MgCl2 3.0 30.0 4.0 20.0 8.0 40.0 
dNTP 4.0 20.0 4.0 20.0 4.0 20.0 
PCRB 2.5 12.5 2.5 12.5 2.5 12.5 
DMSO 5.0 25.0 5.0 25.0 5.0 25.0 
dH2O 7.5 37.5 9.5 47.5 5.5 27.5 
Mix 1(N) 2(B) 3(G) 
Upper Rxn Mix X1 X13 
Tag .25 3.25 
Template 1 #1 13 
PCRB 2.5 32.5 
dH2O 16.25 211.25 
FIG. 3, shoWs a gel shoWing ef?cacy of the probe accord 
ing to the present invention. Adetailed description of the gel 
lanes in FIG. 3 folloW: 
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1 100 bp Ladder 
2 1.0 #1 pr, 2 mM MgCl2, 10 ng DNA Templ. 
3 1.0 #1 pr, 2 mM MgCl2, 40 ng DNA Templ. 
4 1.0 #1 pr, 2 mM MgCl2, 80 ng DNA Templ. 
5 1.0 #1 pr, 3 mM MgCl2, 10 DNA 
*6 1.0 ,ul pr, 3 mM MgCl2, 40 DNA 
*7 1.0 ,ul pr, 3 mM MgCl2, 80 DNA 
*8 2.5 #1 pr, 1 mM MgCl2, 10 
*9 2.5 #1 pr, 1 mM MgCl2, 40 
*10 2.5 #1 pr, 1 mM MgCl2, 80 
11 2.5 #1 pr, 2 mM MgCl2, 10 
12 2.5 #1 pr, 2 mM MgCl2, 40 
13 2.5 #1 pr, 2 mM MgCl2, 80 
14 2.5 #1 pr, 3 mM MgCl2, 10 
15 2.5 #1 pr, 3 mM MgCl2, 40 
*16 2.5 #1 pr, 3 mM MgCl2, 80 
*17 3.0 #1 pr, 2 mM MgCl2, 10 
18 3.0 #1 pr, 2 mM MgCl2, 40 
19 3.0 #1 pr, 2 mM MgCl2, 80 
20 1.0 pr, 2 mM MgCl2, DMSO, 10 
21 1.0 pr, 2 mM MgCl2, DMSO, 40 
22 1.0 pr, 2 mM MgCl2, DMSO, 80 
*23 2.0 pr, 3 mM MgCl2, DMSO, 10 
*24 2.0 pr, 3 mM MgCl2, DMSO, 40 
*25 2.0 pr, 3 mM MgCl2, DMSO, 80 
*26 2.5 pr, 1 mM MgCl2, DMSO, 10 
**27 2.5 pr, 1 mM MgCl2, DMSO, 40 
*28 2.5 pr, 1 mM MgCl2, DMSO, 80 
*29 2.5 pr, 2 mM MgCl2, DMSO, 10 
*30 2.5 pr, 2 mM MgCl2, DMSO, 40 
*31 2.5 pr, 2 mM MgCl2, DMSO, 80 
**32 2.5 pr, 3 mM MgCl2, DMSO, 10 
**33 2.5 pr, 3 mM MgCl2, DMSO, 40 
**34 2.5 pr, 3 mM MgCl2, DMSO, 80. 
(*—rnarks (+) lane, 
**—marks excellent probe) 
EXAMPLE 4 
In an alternative embodiment a RAPD assay may be used 
to detect Sarcocystis neurona. Unlike standard PCR, the 
random ampli?ed polymorphic DNA (RAPD) assays is a 
procedure Which ampli?es DNA fragments Without the use 
of speci?c primers, thus circumventing the need for nucle 
otide sequence information and speci?c primer design.°’7 
These random DNA fragments are often polymorphic 
among species and isolates, behave as dominant alleles, and 
are inherited in a Mendelian fashion. Therefore, not only can 
they be used in the same manner as restriction fragment 
length polymorphic (RFLP) markers to characterize an 
organism’s genome through genetic mapping, but also as a 
means to differentiate species or isolates.8’9 
The present inventors utilize the RAPD assay as a means 
to differentiate four isolates of S. neurona from other coc 
cidial species and have isolated a short DNA fragment Which 
is useful as a speci?c DNA probe for S. neurona. Four 
isolates of Sarcocystis neurona from horses With equine 
protozoal myeloencephalitis and eight species of coccidia 
from the genera Sarcocystis, Toxoplasma or Eimeria Were 
differentiated using the random ampli?ed polymorphic DNA 
(RAPD) assay. A single, common 550-bp DNA fragment 
Was ampli?ed from the DNA of each S. neurona isolate 
using a 16 nucleotide universal primer (TGF): 
Cross-hybridization analysis among S. neurona isolates 
shoWed that DNA fragments had at least partial sequence 
homology. The primer generated several DNA fragments, 
including a 550-bp DNA fragment, from S. cruzi, Eimeria 
falciformis, E. neischulzi, E. ahsata and E. bovis. DNA 
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hybridization analyses indicated no sequence homology 
between these fragments and the 550-bp fragment generated 
from S. neurona. The S. neurona 550-bp DNA fragment also 
did not hybridize With genomic blots of various other 
coccidia. These results evidence that the S. neurona DNA 
fragment 550 bp fragment is also a species-speci?c probe for 
this parasite. 
Diagnostic Assay 
Four geographic isolates of S. neurona Were used; SN 2 
and SN 4 from California,1°’11 Sn 3 from Panama12 and Sn 
5 from Kentucky. Organisms Were isolated from gross spinal 
cord lesions and groWn in bovine monocyte (M617) cell 
cultures as originally described by Dubey et al.13 Merozoites 
Were isolated and puri?ed from cultures as previously 
described by Granstrom et al.3 DNA from S. neurona, S. 
cruzi, S. campestris, Toxoplasma gondii or bovine mono 
cytes Was extracted using proteinase K digestion and phenol/ 
chloroform extraction as described by Gaj adhar et al.14 DNA 
Was extracted from Eimeria tenella, E. falciformis, E. 
nieschulzi, E. ahsata or E. bovis as outlined previously.8 
Each RAPD assay consisted of a 25-;41 reaction volume 
Which contained approximately 50 ng of DNA from each 
species or geographic isolate, 1.5 OU Taq DNA polymerase 
(Promega, Madison, Wis., USA) in 50 mM KCl, 10 mM 
Tris-HCl, pH 9.0, 3.0 mM MgCl2, 0.01% gelatin, 0.1% 
Triton X-100, 0.4 pM primer (TGF; 
5‘-GCACGAACGCGCCACAAA-3‘(SEQ ID N017) and 
200 pM of each dNTP. 
The samples Were overlaid With 25 pl of mineral oil and 
preincubated for 10 min at 94° C. in a DNA Thermal Cycler 
model 480 (Perkin-Elmer Cetus Corporation, NorWalk, 
Conn., USA). This Was folloWed by 40 cycles of 94° C. for 
30 s, 38° C. for 30 s, 72° C. for 45 s, as suggested by Yu and 
Pauls.15 After completion of the thermal cycling reaction, a 
?nal 10-min incubation at 72° C. Was performed. 
DNA fragments generated by PCR Were separated by 
electrophoresis on 1.2% agarose gels in borate buffer and 
visualized by staining With ethidium bromide.16 DNA frag 
ments unique to S. neurona Were isolated from agarose gels 
by band excision and puri?ed using Quiex (Qiagen, 
ChatsWorth, Calif., USA). Putative DNA probe fragments 
Were labelled With [alpha-32F] dATP using Escherichia coli 
DNA polymerase 1 as described by Rigby et al.17 
The putative DNA probe fragments Were analyzed using 
standard hybridization COHd1I1OI1S.16 DNA fragments Were 
applied to Zeta probe GT membranes (BioRad, Hercules, 
Calif.) and baked in vacuo at 80° C. for 2 h. Genomic DNA 
from S. cruzi, S. campestris, T gondii, E. nieschulzi, E. 
ahsata, E. vermiformis, E. coli or bovine monocytes Were 
digested With Pst 1 at 37° C. for 2 h. The resulting DNA 
fragments Were electrophoretically separated in a 0.75% 
agarose gel and transferred to Zeta probe GT membrane by 
capillary action.18 
Hybridization analysis With putative S. neurona-speci?c 
DNA probes Was conducted at 65° C. for 12 h in 10 ml 
hybridization buffer (5><Denhardts, 4><SSC, 0.1% SDS at 65° 
C. for 30 min, and once in 0.5><SSC, 0.1% SDS for 30 min 
at the same temperature. The membranes Were exposed to 
XAR-5 ?lm at —70° C. for 24 h using lighting plus inten 
sifying screens. 
Random ampli?ed polymorphic DNA assays using primer 
TGF generated a single DNA fragment With an electro 
phoretic mobility corresponding to 550 bp in all S. neurona 
isolates. The ampli?cation of only a minute amount of 
product Was detectable from isolate 3. ADNA fragment With 
an identical electrophoretic mobility Was also ampli?ed 
from the DNA of S. campestris, E. falciformis, E. ahsata and 
6,110,665 
13 
E. bovis, but not from bovine monocyte cells. However, 
When the 550-bp DNA fragment from S. neurona (SN 2) Was 
used as a probe, only those DNA fragments ampli?ed from 
the S. neurona isolates hybridized. 
Although 550-bp DNA fragments Were also generated 
from other coccidia, the fragments did not share nucleotide 
sequence homology With S. neurona. Cross-species hybrid 
iZation did not occur When the 550-bp DNA fragment from 
S. neurona (SN 2) Was used to probe Southern transfers of 
genomic DNA isolated from bovine monocyte cells, 
Escherichia coli. E. vermiformis, E. ahsata, E. nieschulzi, T 
gondii, S. campestris or S. cruzi. 
The RAPD assay has been successfully used to differen 
tiate among closely related organisms.9>19’21 It Was found 
that it is possible to identify unique RAPD fragments Which 
could be used as species-speci?c DNA probes. 
In the present study, the RAPD assay differentiated S. 
neurona from S. cruzi and S. campestris, as Well as T gondii 
and ?ve Eimeria spp. 
These data, among geographically distinct isolates of S. 
neurona, suggest that EPM is caused by a single organism. 
The 550-bp DNA fragment generated by the RAPD assay 
has been developed into a species-speci?c probe for S. 
neurona. The recognition of a putative DNA probe has 
facilitated the development of a diagnostic assay for S. 
neurona based on DNA hybridiZation. 
Sarcocystis spp. have a heteroXenous, predator-prey or 
scavenger-carrion life cycle. The de?nitive host(s) and true 
intermediate host(s) of S. neurona are not knoWn. Sarco 
cystis of S. neurona, required for transmission to the de?ni 
tive host, have not been observed in the horse.22 
Consequently, the horse is considered an aberrant, dead-end 
host. Sarcocystis neurona probably cycles normally betWeen 
tWo or more Wildlife species. Although many species have 
been suggested as the true de?nitive host(s) of S. neurona, 
skunks, raccoons or opossums are the most probable. Simi 
lar to EPM, these species are broadly distributed but unique 
to the Western hemisphere. Small rodents or birds are 
speculative but reasonable candidates for the true interme 
diate host(s) of S. neurona. 
While the RAPD assay and resultant probes have imme 
diate application for the differentiation of S. neurona from 
other equine coccidia, an equally important use is the ability 
to discern and solve the parasite’s life cycle by testing 
Sarcocystis spp. from potential hosts. The availability of 
infective stages Will permit the experiments necessary to 
develop effective prevention and control measures for EPM. 
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the equine condition of protoZoal myelitis. 
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SEQUENCE LISTING 
(1) GENERAL INFORMATION: 
(iii) NUMBER OF SEQUENCES: 97 
(2) INFORMATION FOR SEQ ID NO:1 : 
6,110,665 
17 18 
-continued 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 17 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : 
CCATTCCGGA CGCGGGT l7 
(2 ) INFORMATION FOR SEQ ID NO : 2: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 23 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2: 
GGATTTCGGT TCTATTTTGT TGG 2 3 
(2 ) INFORMATION FOR SEQ ID NO: 3: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 19 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3: 
GTTTCAGCCT TGCGACCAT l9 
(2 ) INFORMATION FOR SEQ ID NO: 4: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 17 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4: 
CCAGGCGTGG AGCTGCG l7 
(2) INFORMATION FOR SEQ ID NO:5: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 18 base pairs 
6,110,665 
19 20 
-continued 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5: 
GGTGGTGGTG CATGGCCG l8 
(2 ) INFORMATION FOR SEQ ID NO: 6: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 16 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6: 
GCGCGTGGCC CAGAAC l6 
(2 ) INFORMATION FOR SEQ ID NO: 7: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 18 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: No 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7: 
GCACGAACGC GCCACAAA l8 
(2 ) INFORMATION FOR SEQ ID NO: 8: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 25 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8: 
ATAGTAACCG AACGGATCGC ATTAT 2 5 
(2) INFORMATION FOR SEQ ID NO:9: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 25 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
6,110,665 
21 22 
-continued 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: 
ATAGTAACCG AACGGATCGC ACTAT 25 
(2) INFORMATION FOR SEQ ID NO: 10 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 26 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:lO : 
ATNTCGCNNT CTGAGATCGC GATNAT 26 
(2) INFORMATION FOR SEQ ID NO: 11 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 27 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll : 
NTANNANTCC GNNNGGTTCN NNTNANT 27 
(2) INFORMATION FOR SEQ ID NO: 12 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 25 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:l2 : 
ATAGTAACCG AACGGATCGC ATTAT 25 
(2) INFORMATION FOR SEQ ID NO: 13 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 27 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 





















